Alector Company
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Investors
Funding Status:
IPO
Industry:
Neurodegeneration and aging
Estimated Revenue:
$10M to $50M
Number Of Exists:
101-250
Headquarters:
San Francisco, California, United States
Total Funding:
194500000
Last Funding Date:
2018-07-25
Last Funding Type:
Series E
Employee Number:
101-250
Investors Number:
20
Founded Date:
2013-01-01